Abstract: An immunobooster capable of delivering an immunogen to an individual or animal in a controlled release manner is described. The immunobooster contains an immunogen/hydrophobic polymer matrix with a swelling agent such that the swelling agent can swell in an aqueous environment and burst the matrix. The immunogen is released in a pulsed release manner after a desired time interval has elapsed subsequent to administration of the immunobooster. The immunobooster eliminates the need for multiple administrations of immunogen in order to build lasting immunity. Also described are methods of preparing and using the immunobooster, and kits containing the immunobooster.

Abstract: A drug delivery system useful in aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a controlled, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems and kits containing the drug delivery systems.

Abstract: A drug delivery system useful in treating an individual for a drug dependence is described. One embodiment of the system is useful for aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a controlled, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems in treating other drug dependencies and kits containing the drug delivery systems.

Abstract: A drug delivery system useful in aiding individuals in the cessation of smoking or chewing nicotine containing products is described. The delivery system includes a physical constraint modulation system (PCMS.TM.) containing lobeline. The drug delivery system is capable of delivering lobeline to an individual in a controlled, sustained release manner and providing long-term therapeutic levels of lobeline to the individual. The delivery of lobeline in such a manner reduces or eliminates the individual's smoking or chewing habit. The PCMS may be a biodegradable polymer containing the lobeline capable of subcutaneous or intramuscular injection or implantation into the individual or may be part of a transdermal patch containing lobeline. Also described are methods of using the drug delivery systems and kits containing the drug delivery systems.

Abstract: A therapeutic agent delivery system that includes a biodegradable polymer and a therapeutic agent, the delivery system being coated with a barrier substance that decreases the quantity of the agent released from the system, compared to the quantity of the agent released from a system not coated with the substance, in the forty-eight hours subsequent to the parenteral injection or implantation of the system into a living person or animal.

Abstract: Described and claimed are biologically useful crosslinked copolymers of vinyl pyrrolidone and allylamine suitable for various preventative and therapeutic applications to intact or injured skin. Coatings of these copolymers, either preformed or prepared in situ on the skin may deliver medicaments to the skin, may serve as an iontophoretic medium, may provide electrical contact with the body, may regulate or control moisture loss from injured integument. Monolithic devices for the delivery of pharmaceutically active agents within living tissue may be formulated from these copolymers.

Abstract: Described and claimed are biologically useful crosslinked copolymers of vinyl pyrrolidone and allylamine suitable for various preventative and therapeutic applications to intact or injured skin. Coatings of these copolymers, either preformed or prepared in situ on the skin may deliver medicaments to the skin, may serve as an iontophoretic medium, may provide electrical contact with the body, may regulate or control moisture loss from injured integument. Monolithic devices for the delivery of pharmaceutically active agents within living tissue may be formulated from these copolymers.